Nasus Pharma Ltd. (NSRX) Balance Sheet
NSRX balance sheet, 2025
December 31, 2025 · U.S. dollars$5.0M assets = $2.2M liabilities + $2.8M equity
Both columns are drawn to the same scale: what NSRX owns equals what it owes plus shareholders’ equity. Hover a block for its value.
NSRX financial health
Descriptive bands, not a rating. Fiscal 2025.
NSRX balance sheet trends, 2022–2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Total assets | $417,0002022 | $5.0M2025 | +128.9%/yr | |
| Total liabilities | $3.2M2022 | $2.2M2025 | −11.3%/yr | |
| Shareholders’ equity | −$2.8M2022 | $2.8M2025 | — | |
| Cash & short-term investments | $154,0002022 | $4.3M2025 | +203.0%/yr | |
| Total debt | $1.6M2022 | $118,0002025 | −57.8%/yr | |
| Net cash (debt) | −$1.4M2022 | $4.2M2025 | +$5.6M | |
| Working capital | −$2.8M2022 | $2.7M2025 | +$5.5M | |
| Book value per share | −$0.312022 | $0.352025 | — | |
| Current ratio | 0.132022 | 2.242025 | +2.11 | |
| Shares outstanding | 9.1M2022 | 8.0M2025 | −4.0%/yr |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
NSRX assets
NSRX liabilities and equity
NSRX debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease obligations.
NSRX balance sheet
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | $4.3M | $284,000 | $193,000 | $154,000 |
| Cash & equivalents | $1.2M | $284,000 | $193,000 | $154,000 |
| Short-term investments | $3.0M | $0 | — | — |
| Receivables | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 |
| Other current assets | $569,000 | $173,000 | $251,000 | $263,000 |
| Total current assets | $4.9M | $457,000 | $444,000 | $417,000 |
| Property, plant & equipment (net) | $149,000 | $0 | $0 | $0 |
| Goodwill & intangible assets | $0 | $0 | $0 | $0 |
| Long-term investments | $0 | $0 | $0 | $0 |
| Other non-current assets | $0 | $260,000 | $0 | $0 |
| Total assets | $5.0M | $717,000 | $444,000 | $417,000 |
| Liabilities | ||||
| Accounts payable | $829,000 | $651,000 | $655,000 | $771,000 |
| Short-term debt | $45,000 | $1.8M | $2.5M | $1.6M |
| Total current liabilities | $2.2M | $3.9M | $4.2M | $3.2M |
| Long-term debt | $0 | $0 | $0 | $0 |
| Lease obligations | $118,000 | $0 | — | — |
| Other long-term liabilities | $73,000 | $0 | $0 | $0 |
| Total liabilities | $2.2M | $3.9M | $4.2M | $3.2M |
| Shareholders' equity | ||||
| Common stock & paid-in capital | — | $20,000 | $19,000 | $4,000 |
| Retained earnings (deficit) | −$18.5M | −$12.7M | −$11.1M | −$10.1M |
| Total shareholders' equity | $2.8M | −$3.2M | −$3.8M | −$2.8M |
| Key figures | ||||
| Total debt | $118,000 | $1.8M | $2.5M | $1.6M |
| Net cash (debt) | $4.2M | −$1.5M | −$2.3M | −$1.4M |
| Working capital | $2.7M | −$3.5M | −$3.8M | −$2.8M |
| Tangible book value | $2.8M | −$3.2M | −$3.8M | −$2.8M |
| Book value per share | $0.35 | −$0.35 | −$0.42 | −$0.31 |
| Shares outstanding | 8.0M | 9.1M | 9.1M | 9.1M |
| Current ratio | 2.24 | 0.12 | 0.10 | 0.13 |
| Quick ratio | 1.98 | 0.07 | 0.05 | 0.05 |
| Debt / equity | 0.04 | — | — | — |
| Equity / assets | 55.3% | −448.0% | −855.2% | −667.9% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Dec '24 | Jun '24 | Dec '23 | |
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Cash & short-term investments | $11.8M | $11.8M | $4.3M | $4.3M | $203,000 | $284,000 | $900,000 | $193,000 |
| Cash & equivalents | $7.8M | $7.8M | $1.2M | $1.2M | $203,000 | $284,000 | $900,000 | $193,000 |
| Short-term investments | $4.0M | $4.0M | $3.0M | $3.0M | — | $0 | — | — |
| Receivables | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other current assets | $493,000 | $493,000 | $569,000 | $569,000 | $88,000 | $173,000 | $29,000 | $251,000 |
| Total current assets | $12.3M | $12.3M | $4.9M | $4.9M | $291,000 | $457,000 | $929,000 | $444,000 |
| Property, plant & equipment (net) | $138,000 | $138,000 | $149,000 | $149,000 | $0 | $0 | $0 | $0 |
| Goodwill & intangible assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-term investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other non-current assets | $0 | $0 | $0 | $0 | $348,000 | $260,000 | $91,000 | $0 |
| Total assets | $12.4M | $12.4M | $5.0M | $5.0M | $639,000 | $717,000 | $1.0M | $444,000 |
| Liabilities | ||||||||
| Accounts payable | $347,000 | $347,000 | $829,000 | $829,000 | $664,000 | $651,000 | $652,000 | $655,000 |
| Short-term debt | $54,000 | $54,000 | $45,000 | $45,000 | — | $1.8M | $3.8M | — |
| Total current liabilities | $1.4M | $1.4M | $2.2M | $2.2M | $5.0M | $3.9M | $5.7M | $4.2M |
| Long-term debt | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Lease obligations | $103,000 | — | $118,000 | — | — | $0 | — | — |
| Other long-term liabilities | $49,000 | $49,000 | $73,000 | $73,000 | $0 | $0 | $0 | $0 |
| Total liabilities | $1.5M | $1.5M | $2.2M | $2.2M | $5.0M | $3.9M | $5.7M | $4.2M |
| Shareholders' equity | ||||||||
| Common stock & paid-in capital | — | — | — | — | — | $20,000 | $4,000 | — |
| Retained earnings (deficit) | −$24.5M | −$24.5M | −$18.5M | −$18.5M | −$13.9M | −$12.7M | −$12.0M | −$11.1M |
| Total shareholders' equity | $11.0M | $11.0M | $2.8M | $2.8M | −$4.3M | −$3.2M | −$4.7M | −$3.8M |
| Key figures | ||||||||
| Total debt | $103,000 | $103,000 | $118,000 | $118,000 | — | $1.8M | $3.8M | — |
| Net cash (debt) | $11.7M | $11.7M | $4.2M | $4.2M | — | −$1.5M | −$2.9M | — |
| Working capital | $10.9M | $10.9M | $2.7M | $2.7M | −$4.7M | −$3.5M | −$4.8M | −$3.8M |
| Tangible book value | $11.0M | $11.0M | $2.8M | $2.8M | −$4.3M | −$3.2M | −$4.7M | −$3.8M |
| Book value per share | $0.99 | $0.99 | $0.31 | $0.31 | −$0.48 | −$0.45 | −$0.68 | −$0.55 |
| Shares outstanding | 11.1M | 11.1M | 9.0M | 9.0M | 9.1M | 7.2M | 6.9M | 6.9M |
| Current ratio | 8.77 | 8.77 | 2.24 | 2.24 | 0.06 | 0.12 | 0.16 | 0.10 |
| Quick ratio | 8.42 | 8.42 | 1.98 | 1.98 | 0.04 | 0.07 | 0.16 | 0.05 |
| Debt / equity | 0.01 | 0.01 | 0.04 | 0.04 | — | — | — | — |
| Equity / assets | 88.3% | 88.3% | 55.3% | 55.3% | −675.1% | −448.0% | −457.2% | −855.2% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported (latest annual report filed March 25, 2026); data from EODHD.
NSRX financial position
At the end of fiscal 2025 (December 31, 2025), Nasus Pharma had total assets of $5.0 million (up 597.9% from a year earlier), total liabilities of $2.2 million and shareholders' equity of $2.8 million. It held $4.3 million in cash and short-term investments against $0.1 million of debt, a net cash position of $4.2 million. Its current ratio was 2.24. In the latest quarter (ended June 30, 2026) total assets were $12.4 million and equity $11.0 million.
Related: NSRX income statement, NSRX cash flow statement, NSRX key metrics. See the NSRX stock overview for the latest quote and news.
NSRX balance sheet FAQ
What are Nasus Pharma's total assets?
Nasus Pharma reported total assets of $5.0 million at the end of fiscal 2025 (December 31, 2025), compared with $0.7 million a year earlier.
How much debt does Nasus Pharma have?
Nasus Pharma had $0.1 million of total debt at the end of fiscal 2025, including short-term borrowings and lease obligations. Its debt-to-equity ratio was 0.04.
How much cash does Nasus Pharma have?
Nasus Pharma held $4.3 million in cash and short-term investments at the end of fiscal 2025; with $0.1 million of debt that is net cash of $4.2 million.
What is Nasus Pharma's book value?
Nasus Pharma's shareholders' equity (book value) was $2.8 million at the end of fiscal 2025, or $0.35 per share.
What is Nasus Pharma's current ratio?
Nasus Pharma had current assets of $4.9 million and current liabilities of $2.2 million, a current ratio of 2.24 (it can cover its short-term obligations).